FDA-approved
Sexual & reproductive
Lutetium Lu-177 vipivotide tetraxetan
Evidence
FDA approved
Class
Radioligand therapy targeting PSMA
KEY TAKEAWAY
Lutetium Lu 177 vipivotide tetraxetan is a small PSMA-binding peptide-like molecule carrying radioactive lutetium. It is sold as Pluvicto. The FDA approved Pluvicto in 2022 for PSMA-positive metastatic castration-resistant prostate cancer, and later for an earlier stage of disease.
Written by the Veylo editorial team · Updated
November 2026
What it is
Radioligand therapy targeting PSMA
Approved for
PSMA-positive metastatic castration-resistant prostate cancer
Key fact
The FDA approved Pluvicto in 2022 for PSMA-positive metastatic castration-resistant prostate cancer, and later for an earlier stage of disease.
Route
Intravenous infusion in a series of treatments
Evidence strength
FDA approved
Lutetium Lu 177 vipivotide tetraxetan is a small PSMA-binding peptide-like molecule carrying radioactive lutetium. It is sold as Pluvicto.
It binds prostate-specific membrane antigen on prostate cancer cells and delivers radiation directly to them.
The FDA approved Pluvicto in 2022 for PSMA-positive metastatic castration-resistant prostate cancer, and later for an earlier stage of disease.
PSMA-positive metastatic castration-resistant prostate cancer.
Dry mouth, fatigue, nausea, low blood counts and kidney effects are the main concerns. Radiation-safety precautions apply.
U.S. FDA prescribing information for Lutetium Lu-177 vipivotide tetraxetan. DailyMed, National Library of Medicine.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.